ReviewThyroid : official journal of the American Thyroid Association2011
Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier.
Review in Thyroid : official journal of the American Thyroid Association, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Stereotactic radiotherapy (SRT) for differentiated thyroid cancer (DTC) oligometastases: an AIRO (Italian association of radiotherapy and clinical oncology) systematic review.La Radiologia medica · 2022Pooled it
- Case Report: A rare case of thyroid metastasis from breast cancer.Frontiers in oncology · 2025Article
- Metastatic differentiated thyroid cancer: worst prognosis in patients with metachronous metastases.Endocrine · 2023Article
- Recurrence of Papillary Thyroid Cancer: A Systematic Appraisal of Risk Factors.The Journal of clinical endocrinology and metabolism · 2022Article
- CircRNA casein kinase 1 gamma 1 (circ-CSNK1G1) plays carcinogenic effects in thyroid cancer by acting as miR-149-5p sponge and relieving the suppression of miR-149-5p on mitogen-activated protein kinase 1 (MAPK1).Journal of clinical laboratory analysis · 2022Article
- Progression and dormancy in metastatic thyroid cancer: concepts and clinical implications.Endocrine · 2020Review
- Metastatic Anaplastic Thyroid Carcinoma in Complete Remission: Morphological, Molecular, and Clinical Work-Up of a Rare Case.Endocrine pathology · 2020Article
- Circ_0058124 Upregulates MAPK1 Expression to Promote Proliferation, Metastasis and Metabolic Abilities in Thyroid Cancer Through Sponging miR-940.OncoTargets and therapy · 2020Article
- Clonal Reconstruction of Thyroid Cancer: An Essential Strategy for Preventing Resistance to Ultra-Precision Therapy.Frontiers in endocrinology · 2019Article
- Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly.Current oncology reports · 2018Review
- RCAN1-4 is a thyroid cancer growth and metastasis suppressor.JCI insight · 2017Article
- [Lymph node and distant metastases of thyroid gland cancer. Metastases in the thyroid glands].Der Pathologe · 2015Review
- Natural history of small radioiodine-avid bone metastases that have no structural correlate on imaging studies.Endocrine · 2014Article
- Metastatic mechanisms in follicular cell-derived thyroid cancer.Endocrine-related cancer · 2013Review
- Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions.Minerva endocrinologica · 2012Review
- Thyroid Cancer Initially Presenting Compression Fracture without Common Thyroid Symptoms.Annals of rehabilitation medicine · 2012Article
- SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2.The Journal of experimental medicine · 2012Article
- Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
- Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer?Frontiers in endocrinology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
backgroundMetastatic dormancy, or the ability of cancer cells to survive but not progress in metastatic environments, is now recognized to be a common occurrence in cancer. SUMMARY: From a clinical perspective, this phenomenon is common in metastatic well-differentiated thyroid cancer, whereby patients often present with distant metastases that remain stable for years after removal of the primary tumor and subsequent treatment. Experimental data suggest that metastases can develop throughout the life of a cancer and that progression in the distant environment depends on the biology of the cancer cells that metastasize as well as that of the various microenvironments they encounter. A firm understanding of how thyroid cancer cell progression is regulated in different metastatic environments is necessary to devise effective therapies targeting progressive metastatic thyroid cancer.
conclusionIn this review, current models of metastatic progression and factors that regulate late-stage metastatic progression that are particularly relevant for thyroid cancer are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.